HIM
JNCE

Hillhouse Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Hillhouse Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-130,000
Closed -$2.02M – 49
2017
Q3 		$2.02M Hold
130,000
– – 0.03% 47
2017
Q2 		$1.82M Sell
130,000
-40,300
-24% -$863K 0.03% 57
2017
Q1 		$3.75M Buy
+170,300
New +$3.61M 0.07% 46

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Hillhouse Investment Management's JNCE Position: Q4 2017 in Review

Hillhouse Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2017, closing a stake of 130,000 shares — an estimated $2.02M sold.

Hillhouse Investment Management first reported a position in JNCE in Q1 2017 and held it in 3 quarters. The position peaked at $3.75M in Q1 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q4 2017.

  • Hillhouse Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 130,000 Jounce Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $2.02M.
  • Hillhouse Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Hillhouse Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.75M in Q1 2017.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Hillhouse Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.